Advertisement

Topics

Latest Cancer NewsRSS

02:21 EDT 28th April 2017 | BioPortfolio

Zymeworks Announces Pricing of Initial Public Offering

Zymeworks Inc. (“Zymeworks”) today announced the pricing of its initial public offering of 4,500,000 common shares at a price to the public of U.S.$13.00 per share. In addition, Zymeworks has granted the underwriters a 30-day over-allotment option to purchase up to an additional 675,000 common shares at the initial public offering price, less underwrit...

Cytune Pharma SAS Pharmaceuticals Healthcare Deals and Alliances Profile [Updated: 20032017] Prices from USD $250

SummaryCytune Pharma SAS Cytune is a biotechnology company that develops immunotherapeutic agents for the treatment of cancer and infectious diseases. The company's product portfolio includes recombinant proteins and monoclonal antibodies. Cytune's flagship product, CYP0150 is a recombinant protein which decreases metastasis numbers, tumor progression and increases patient survival. The company is...

Tiziana Life Sciences Plc TILS Pharmaceuticals Healthcare Deals and Alliances Profile [Updated: 22032017] Prices from USD $250

SummaryTiziana Life Sciences Plc Tiziana formerly Alexander David Investments is a clinical stage biotechnology company that discovers and develops innovative drugs for the treatment of various types of cancer with particular focus on late stage metastases. Tiziana' discovery of the Bcl3 gene playing a prominent role in halting cancer metastasis forms the core of its RD efforts. Its RD pipeline in...

FDA Approves Regorafenib for Liver Cancer

The FDA has approved regorafenib (Stivarga) for the second-line treatment of hepatocellular carcinoma (HCC) for patients who have previously received sorafenib.

Swissx Labs AG Launches in U.S. with the Finest CBD Oil on Earth

Created “For the Higher Good” in Switzerland, the oil extracted from hemp seeds debuted at Coachella and in select health food stores in Malibu and Beverly Hills; Swissx developing custom CBD products tuned for various health needs and aiding National Cancer Institute in its research Malibu, CA (PRWEB) April 27, 2017 Offering the purest product of its kind, Swissx Labs AG has launched in the ...

The UK’s NHS Cancer Drugs Fund has Failed to Help Patients

The Cancer Drugs Fund has failed to prove it provides a real benefit for cancer patients. Should other European countries refrain from adopting the model? After analyzing 29 drugs for 47 cancer indications approved through the Cancer Drugs Fund (CDF), ... This awesome article The UK’s NHS Cancer Drugs Fund has Failed to Help Patients appeared first on Labiotech.eu. Be kind and don't copy it ...

Ignyta Updates Progress towards Entrectinib Dual TRK and ROS1 NDA Submissions

Entrectinib program is more than 85% enrolled to goal for the primary efficacy analysis to support a TRK tissue agnostic NDA submission More than 50 patients with ROS1 fusion-positive NSCLC enrolled; interim data from 32 of these patients demonstrated 75% (24 of 32) confirmed RECIST ORR and 17.2 months DOR ...

University of Texas MD Anderson Cancer Center Pharmaceuticals Healthcare Deals and Alliances Profile [Updated: 22032017] Prices from USD $250

SummaryUniversity of Texas MD Anderson Cancer Center MD Anderson is one of the leading cancer care centers in the US. It is one of the three original comprehensive cancer care centers designated by the National Cancer Act of 1971 in the US and is affiliated to University of Texas Health. MD Anderson provides cancer treatment, cancer research, education and researchbased prevention of both common a...

The Cleveland Clinic Foundation Pharmaceuticals Healthcare Deals and Alliances Profile [Updated: 22032017] Prices from USD $250

SummaryThe Cleveland Clinic Foundation Cleveland Clinic is a nonprofit, multispecialty medical organization, providing clinical and hospital care services. It operates through a network of hospitals and clinics. It integrates its services with research and educational institutes. Cleveland Clinic's network of facilities includes regional hospitals; regional care centers; a children's hospital; a r...

Cellectis CEO Selected as Speaker for 2017 Milken Institute Global Conference

Dr. André Choulika to Serve as Panelist for “Humankind vs. Cancer: The Scorecard” Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T

STAT Plus: Q&A: Startup bringing precision medicine to pneumonia

Arsanis thinks monoclonal antibody drugs, which have shown success in treating cancer and autoimmune disease, might be a smart substitute for antibiotics.

Aspyrian announces the presentation of clinical data of its investigational therapy RM-1929 demonstrating significant anti-cancer response in recurrent Head and Neck Cancer patients who have failed all existing treatment options

SAN DIEGO, April 27, 2017 /PRNewswire/ -- Aspyrian Therapeutics, Inc., a biotechnology company developing precision-targeted cancer therapies based on the proprietary Photoimmunotherapy (PIT) platform, today announced that findings from an ongoing clinical trial of its proprietary investigational compound, RM-1929, were presented at the American Head & Neck Society meeting, April 27, in S...

Juno Therapeutics to Report First Quarter 2017 Financial Results on Thursday, May 4

Juno Therapeutics, Inc. (NASDAQ: JUNO) will announce financial results for the first quarter 2017 on Thursday, May 4, 2017, after the close of U.S.-based financial markets. Following the announcement, Juno management will host a conference call and live webcast to provide a business update and discuss financial results beginning at 2:00 p.m. Pacific Time (...

Seattle Genetics Reports First Quarter 2017 Financial Results

-First Quarter 2017 Revenues Were $109.1 Million, Including $70.3 Million in ADCETRIS® (Brentuximab Vedotin) U.S. and Canada Net Sales- -Top-Line Data from ADCETRIS Phase 3 ECHELON-1 Trial Expected in 2017- -ADCETRIS Supplemental Biologics License Application for Cutaneous T-Cell Lymphoma Planned in Mid-2017- -Regulatory ...

Bayer Receives FDA Approval for Stivarga® (regorafenib) for the Second-Line Systemic Treatment of Liver Cancer

WHIPPANY, N.J., April 27, 2017 /PRNewswire/ -- Bayer announced today that the U.S. Food and Drug Administration (FDA) approved Stivarga® (regorafenib) tablets for the second-line treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with Nexavar® (sorafenib).2 Stivarga is the first and only treatment to demonstrate significant improvement in overall surv...

Stivarga receives expanded approval to include hepatocellular carcinoma

Brian BerkThe drug, manufactured by Bayer HealthCare Pharmaceuticals, is the first FDA-approved treatment for a liver cancer in almost a decade. read more

American Brain Foundation Presents Prestigious Public Leadership in Neurology Award to B. Smith and Dan Gasby

ABF Honors Alzheimer's Advocates Minneapolis, Minnesota (PRWEB) April 27, 2017 The American Brain Foundation last night presented B. Smith and her husband Dan Gasby the 2017 Public Leadership in Neurology Award (PLINA). The couple joins a prestigious list of past PLINA winners, including journalist Bob Woodruff, retired professional athlete Tedy Bruschi, Vice President Walter Mondale, actor M...

CytRx Corporation Announces Proposed Public Offering of Common Stock

LOS ANGELES, April 27, 2017 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology today announced a proposed public offering of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be consummated, or as to the actual size or terms ...

In-telligent Partners with Susan G. Komen Chicago to Help End Breast Cancer

Alliance between In-telligent and Komen Chicago to enhance breast cancer awareness through accessible, innovative communications technology Chicago, Illinois (PRWEB) April 27, 2017 Susan G. Komen Chicago, a non-profit organization focused on ending breast cancer, has partnered with communications company In-telligent to quickly and easily distribute targeted messages that spread breast cancer awa...

Bristol-Myers surprises with continued Opdivo growth

Despite setbacks in its clinical program, Bristol-Myers is still firmly committed to the lung cancer space and has laid out a broad program for its assets. 

New ASTRO Guidelines for Oropharyngeal Cancer

In this interview we discuss new clinical guidelines from ASTRO on the use of radiotherapy in treating oropharyngeal cancer.

Volunteers Urge Congressional Support for Funding Science Programs, Higher Education

Nearly 50 volunteers urging support for photonics programs and education visited Congressional offices on Wednesday 26 April as part of a Congressional Visits Day supported by SPIE, the international society for optics and photonics, and other partners in the National Photonics Initiative. The volunteers asked for opposition to proposed funding cuts, and emphasized the vital role of optics and pho...

Accuray Third Quarter Gross Orders Increase 49% YoY; Backlog Up 21%

SUNNYVALE, Calif., April 27, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the third fiscal quarter and nine months ended March 31, 2017. Fiscal Third Quarter Highlights Ending backlog increased 21 percent year-over-year to $450.0 million; gross orders increased 49 percent to $83.8 million; net orders were $71.8 million ...

Moderna Announces Positive Interim Phase 1 Clinical Data Demonstrating First mRNA Vaccine Candidate, mRNA-1440, Induces High Levels of Immunogenicity

-100% of subjects in 100 µg intramuscular (IM) cohort achieved HAI titers that are accepted correlate of seroprotection against seasonal flu- -mRNA-1440 safe and well tolerated; tolerability consistent with approved vaccines- -Data published in the journal Molecular Therapy; First human proof-of-concept data from Moderna’s novel...

Pharmacotyping Pancreatic Cancer Patients in the Future: Two Approaches – ORGANOIDS by David Tuveson and Hans Clevers and/or MICRODOSING Devices by Robert Langer

Pharmacotyping Pancreatic Cancer Patients in the Future: Two Approaches – ORGANOIDS by David Tuveson and Hans Clevers and/or MICRODOSING Devices by Robert Langer Curator: Aviva Lev-Ari, PhD, RN   This curation provides the resources for edification on Pharmacotyping Pancreatic Cancer Patients in the Future   Professor Hans Clevers at Clevers Group, Hubrecht University https://www...

Quick Search
Advertisement
 

review and buy Cancer market research data and corporate reports here